Shamik J. Parikh Buys 7,500 Shares of Humacyte, Inc. (NASDAQ:HUMA) Stock

Shamik J. Parikh, an insider at Humacyte, Inc. (NASDAQ:HUMA), purchased 7,500 shares at $1.55 each, totaling $11,625, on April 10th. This acquisition increases his ownership in the company. Following the transaction, HUMA shares traded up 2.9% to $1.58. Humacyte reported a quarterly EPS of ($0.16), exceeding estimates, with revenue of $7.23 million. Analysts maintain a consensus "Buy" rating with a price target of $13.71. Institutional investors hold 44.71% of Humacyte's stock, reflecting significant interest in the company.

Humacyte, Inc. (NASDAQ:HUMA - Get Free Report) insider Shamik J. Parikh purchased 7,500 shares of the stock in a transaction that occurred on Thursday, April 10th. The shares were purchased at an average price of $1.55 per share, for a total transaction of $11,625.00. Following the completion of the purchase, the insider now directly owns 7,500 shares of the company's stock, valued at approximately $11,625. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.

Humacyte Trading Up 2.9 %

HUMA stock traded up $0.05 during trading on Monday, hitting $1.58. 1,142,258 shares of the stock traded hands, compared to its average volume of 3,554,488. The stock has a market cap of $228.13 million, a price-to-earnings ratio of -1.18 and a beta of 1.62. Humacyte, Inc. has a one year low of $1.15 and a one year high of $9.97. The company has a 50 day simple moving average of $2.87 and a 200 day simple moving average of $4.16.

Humacyte (NASDAQ:HUMA - Get Free Report) last announced its earnings results on Friday, March 28th. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.07. The business had revenue of $7.23 million during the quarter, compared to analyst estimates of $0.64 million. As a group, analysts predict that Humacyte, Inc. will post -1.27 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

HUMA has been the topic of a number of research reports. D. Boral Capital restated a "buy" rating and set a $25.00 price objective on shares of Humacyte in a research report on Wednesday, March 26th. HC Wainwright restated a "buy" rating and issued a $15.00 price objective on shares of Humacyte in a research note on Wednesday, March 12th. Finally, Benchmark reiterated a "buy" rating on shares of Humacyte in a research report on Thursday, February 27th. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus price target of $13.71.

Check Out Our Latest Stock Report on Humacyte

Institutional Trading of Humacyte

Several large investors have recently made changes to their positions in HUMA. Woodline Partners LP raised its holdings in shares of Humacyte by 235.7% in the fourth quarter. Woodline Partners LP now owns 2,848,802 shares of the company's stock valued at $14,386,000 after buying an additional 2,000,268 shares during the last quarter. State Street Corp increased its position in Humacyte by 66.1% in the 3rd quarter. State Street Corp now owns 4,764,155 shares of the company's stock valued at $25,917,000 after acquiring an additional 1,895,529 shares in the last quarter. CenterBook Partners LP bought a new position in shares of Humacyte in the fourth quarter worth about $6,463,000. Brevan Howard Capital Management LP lifted its position in shares of Humacyte by 2,795.1% during the fourth quarter. Brevan Howard Capital Management LP now owns 876,340 shares of the company's stock worth $4,426,000 after purchasing an additional 846,070 shares in the last quarter. Finally, Vanguard Group Inc. grew its stake in shares of Humacyte by 10.8% during the fourth quarter. Vanguard Group Inc. now owns 5,602,684 shares of the company's stock valued at $28,294,000 after purchasing an additional 543,995 shares during the last quarter. Institutional investors own 44.71% of the company's stock.

About Humacyte

(Get Free Report)

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.

Five stocks we like better than Humacyte
3 Best Fintech Stocks for a Portfolio Boost
Top 3 Large Cap Stocks Insiders Bought in Q1: Buy, Sell, or Hold
Health Care Stocks Explained: Why You Might Want to Invest
3 Hot New IPOs Defying the 2025 Market Slump
How to Most Effectively Use the MarketBeat Earnings Screener
3 High-Yield Dividend Stocks Trading at a Discount

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Humacyte Right Now?

Before you consider Humacyte, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Humacyte wasn't on the list.

While Humacyte currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here